BTIG analyst Ryan Zimmerman raised the firm’s price target on Globus Medical (GMED) to $94 from $91 and keeps a Buy rating on the shares after its Q4 earnings beat. The majority of the earnings call focus was on the Nevro (NVRO) transaction, strategic rationale, and financial impact, and while the management demurred from getting too detailed given the pending closure, the firm expects meaningful accretion in FY26, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical’s Promising Outlook: Strong Financials, Strategic Acquisitions, and Continued Innovation Drive ‘Buy’ Rating
- Globus Medical price target lowered to $93 from $95 at Wells Fargo
- Buy Rating for Globus Medical Driven by Strong Financial Performance and Strategic Acquisitions
- Globus Medical Reports Strong 2024 Financial Performance
- Globus Medical sees FY25 EPS $3.40-$3.50, consensus $3.43